FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563576689> ?p ?o ?g. }

• W2563576689 abstract "Abstract Abstract 4875 Background: Some studies have showed high activity for low-dose radiotherapy (LDRT) in low-grade Non-Hodgkin Lymphoma (NHL). However, this therapeutic approach is often forgotten and other approaches are used - chemotherapy and/or conventional radiotherapy - associated with greater toxicity. The efficacy of total body LDRT (1.5–2 Gy, fractions 0.1–0.25 Gy in 2 – 5 times a week) in disseminated disease is associated with 10 year progression free survival (PFS) of 15 – 25%, with response rates of 70 – 90% (Gérard et al., IJ Radiation Oncology 2010; 78), despite hematologic toxicity and leukemogenic effects. Although its mechanism of action is unknown, its effectiveness has been confirmed (Jones et al., Cancer 1973; 32) suggesting that low dose radiation induces localized lymphocytes apoptosis that can trigger local and systemic benefits. More recently, LDRT was used in palliative treatment for patients with localized disease (4Gy into two fractions, for 3 days) with a low toxicity, and with an objective response (partial or complete) in 24/37 patients, 89% (G Ganem et al., Hematol Oncol1997; 42). Objectives: To assess the response to treatment with LDRT. Explore the predictive factors of response. Determine the progression-free survival (PFS) after LDRT. We will present PFS after LDRT and compare PFS in second line treatment: LDRT vs convencional chemotherapy. Methods: Retrospective study of 44 patients with new or recurrent NHL, treated with LDRT (4Gy in 2 fractions) in 1stor more lines, in a cancer care centre between 2004 and 2011. All transformed lymphomas were excluded (4 patients), as well all diagnosis that weren't centrally reviewed. Patients with complete resolution of the disease according to clinical and/or image studies were considered to have achieved complete response (CR). Results: We identified 40 patients undergoing LDRT, with a median follow-up of 69,5 months after LDRT ([28–87]). 52,5% (n = 21) were male, median age at the time of LDRT was 69 years ([31–85]). 75% of patients (n = 30) had follicular NHL, 12,5% (n = 5) Mantle cell NHL, 10% (n = 4) Marginal Zone NHL and 2,5% (n = 1) lymphoplasmacytic lymphoma. The median numbers of lines of chemotherapy completed before LDRT were 2 lines ([0–5]). There wasn't any impact on PFS on using Rituximab containing regimens after LDRT (p> 0,05). The overall response rate to LDRT was 92,5% (n = 37): 42,5% (n = 17) achieved complete response (CR), 50% (n = 20) partial response (PR) and 7,5% (n = 3) had disease progression. There weren't any treatment related toxicities, nor was histological transformation recorded after treatment with LDRT. The logistic regression analysis showed that irradiated areas with dimension <40mm are an independent predictive factor of response (p <0,031, 95% CI [1,268-133,285]). We find a median PFS of 4 months ([0–72]) for patients that went on LDRT, and 50% of these patients relapsed after a median 5 months ([0–35]). 56,5% (n = 13) showed relapse at the same location of the irradiated area. Patients who have completed one chemotherapy scheme after relapsing following LDRT, showed a rate of 6 months-PFS of 50% such as the patients that have done a second LDRT treatment. Concerning follicular NHL patients who relapsed after 1st line conventional chemotherapy, 43,8% (n = 7) were treated with LDRT and 56,2% (n = 9) were treated with conventional 2nd line chemotherapy. Comparing these two groups of patients, there weren't any difference for PFS for both groups (mean 9,5 vs 9 months p> 0,05, for LDRT vs 2ndline chemotherapy), for equal overall survival. Conclusion: LDRT is an effective treatment for patients with relapsed or recurrent advanced stage NHL. We can obtain high response rates with negligible toxicity. In the treatment of first relapse, PFS is similar when using LDRT or 2nd line chemotherapy. Considering that Rituximab promotes a synergistic effect with LDRT-induced apoptosis and decrease the cell turnover (Skvortsova I et al., J Radiat Res (Tokyo) 2006), comparative studies with conventional chemotherapy regimens should be promoted. Treatment with conventional radiotherapy should be used in patients with relapsed low-stage and localized disease, having curative intention or locally controlling involved areas. Disclosures: No relevant conflicts of interest to declare." @default.
• W2563576689 created "2017-01-06" @default.
• W2563576689 creator A5010365092 @default.
• W2563576689 creator A5012491849 @default.
• W2563576689 creator A5012718986 @default.
• W2563576689 creator A5022683916 @default.
• W2563576689 creator A5027874480 @default.
• W2563576689 creator A5034189673 @default.
• W2563576689 creator A5040350966 @default.
• W2563576689 creator A5048853947 @default.
• W2563576689 creator A5049279419 @default.
• W2563576689 creator A5056762017 @default.
• W2563576689 creator A5056921940 @default.
• W2563576689 creator A5057879270 @default.
• W2563576689 creator A5074675823 @default.
• W2563576689 creator A5075728620 @default.
• W2563576689 creator A5076384027 @default.
• W2563576689 date "2012-11-16" @default.
• W2563576689 modified "2023-10-03" @default.
• W2563576689 title "Low-Dose Radiotherapy in Patients with Non Hodgkin Lymphoma" @default.
• W2563576689 doi "https://doi.org/10.1182/blood.v120.21.4875.4875" @default.
• W2563576689 hasPublicationYear "2012" @default.
• W2563576689 type Work @default.
• W2563576689 sameAs 2563576689 @default.
• W2563576689 citedByCount "0" @default.
• W2563576689 crossrefType "journal-article" @default.
• W2563576689 hasAuthorship W2563576689A5010365092 @default.
• W2563576689 hasAuthorship W2563576689A5012491849 @default.
• W2563576689 hasAuthorship W2563576689A5012718986 @default.
• W2563576689 hasAuthorship W2563576689A5022683916 @default.
• W2563576689 hasAuthorship W2563576689A5027874480 @default.
• W2563576689 hasAuthorship W2563576689A5034189673 @default.
• W2563576689 hasAuthorship W2563576689A5040350966 @default.
• W2563576689 hasAuthorship W2563576689A5048853947 @default.
• W2563576689 hasAuthorship W2563576689A5049279419 @default.
• W2563576689 hasAuthorship W2563576689A5056762017 @default.
• W2563576689 hasAuthorship W2563576689A5056921940 @default.
• W2563576689 hasAuthorship W2563576689A5057879270 @default.
• W2563576689 hasAuthorship W2563576689A5074675823 @default.
• W2563576689 hasAuthorship W2563576689A5075728620 @default.
• W2563576689 hasAuthorship W2563576689A5076384027 @default.
• W2563576689 hasConcept C121608353 @default.
• W2563576689 hasConcept C126322002 @default.
• W2563576689 hasConcept C143998085 @default.
• W2563576689 hasConcept C2776694085 @default.
• W2563576689 hasConcept C2779338263 @default.
• W2563576689 hasConcept C2780739268 @default.
• W2563576689 hasConcept C29730261 @default.
• W2563576689 hasConcept C2989005 @default.
• W2563576689 hasConcept C509974204 @default.
• W2563576689 hasConcept C71924100 @default.
• W2563576689 hasConceptScore W2563576689C121608353 @default.
• W2563576689 hasConceptScore W2563576689C126322002 @default.
• W2563576689 hasConceptScore W2563576689C143998085 @default.
• W2563576689 hasConceptScore W2563576689C2776694085 @default.
• W2563576689 hasConceptScore W2563576689C2779338263 @default.
• W2563576689 hasConceptScore W2563576689C2780739268 @default.
• W2563576689 hasConceptScore W2563576689C29730261 @default.
• W2563576689 hasConceptScore W2563576689C2989005 @default.
• W2563576689 hasConceptScore W2563576689C509974204 @default.
• W2563576689 hasConceptScore W2563576689C71924100 @default.
• W2563576689 hasLocation W25635766891 @default.
• W2563576689 hasOpenAccess W2563576689 @default.
• W2563576689 hasPrimaryLocation W25635766891 @default.
• W2563576689 hasRelatedWork W2001744336 @default.
• W2563576689 hasRelatedWork W2017258111 @default.
• W2563576689 hasRelatedWork W2044384835 @default.
• W2563576689 hasRelatedWork W2183352065 @default.
• W2563576689 hasRelatedWork W2206889833 @default.
• W2563576689 hasRelatedWork W2347867967 @default.
• W2563576689 hasRelatedWork W2387327279 @default.
• W2563576689 hasRelatedWork W2391151401 @default.
• W2563576689 hasRelatedWork W2514024584 @default.
• W2563576689 hasRelatedWork W2549403581 @default.
• W2563576689 hasRelatedWork W2560299325 @default.
• W2563576689 hasRelatedWork W2560424591 @default.
• W2563576689 hasRelatedWork W2568779533 @default.
• W2563576689 hasRelatedWork W2594599231 @default.
• W2563576689 hasRelatedWork W2739337824 @default.
• W2563576689 hasRelatedWork W2897863924 @default.
• W2563576689 hasRelatedWork W2979293318 @default.
• W2563576689 hasRelatedWork W2979920554 @default.
• W2563576689 hasRelatedWork W2979932463 @default.
• W2563576689 hasRelatedWork W3030371218 @default.
• W2563576689 isParatext "false" @default.
• W2563576689 isRetracted "false" @default.
• W2563576689 magId "2563576689" @default.
• W2563576689 workType "article" @default.